

Sample content

Alzheimer's Disease

Disease Landscape & Forecast

Published: November 2024

About Disease Landscape & Forecast

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.



What are the sizes of the diagnosed, drug-treatable, and/or drug-treated populations?



What is the current treatment landscape?



What products are in development, and what is their launch potential and future positioning?



What is the market outlook of sales and patient share for the next 10 years?



What are the drivers and constraints of market growth, and what events will most impact the market's trajectory?



What unmet needs and opportunities exist?

Methodology and scope


Market forecast

- **Forecast:** Annualized drug-level sales and patient share of key Alzheimer’s disease (AD) therapies from 2023-2033, segmented by brands/generics.
- **Epidemiology:** Total, diagnosed, and drug-treated prevalent cases of AD by country.
- **Market segmentations:** MCI due to AD, mild AD, moderate AD, and severe AD.
- **Additional content:** Downloadable Excel files containing detailed forecast assumptions and visual outputs.

Primary market research

- Interviews with 23 thought-leading neurologists across the G7.
- Data and insights leveraged from physician surveys conducted by Clarivate in AD to model current and future market dynamics.

Geography




Key therapies covered

Phase 2 / 3 / pre-registration	<ul style="list-style-type: none">• Lecanemab IV/SC (Eisai / Biogen)• Remternetug (Eli Lilly)• Semaglutide (Novo Nordisk)• Auvelity (AXS-05; Axsome)• Cobenfy (Bristol Myers Squibb)• Trontinemab (Roche)• BMS-986446 (Bristol Myers Squibb / Prothena)• Posdinemab (Janssen)
Marketed	<ul style="list-style-type: none">• Lecanemab IV (Eisai / Biogen’s Legembi)• Rexulti (Otsuka / Lundbeck)• Donanemab (Eli Lilly’s Kisunla)• Brexpiprazole (Otsuka / Lundbeck’s Rexulti)• Donepezil patch (Corium’s Adlarity; Teikoku Pharma’s Allydone)

Report table of contents

1. **Executive Summary**
2. **Key Updates**
3. **Market Forecast**
 - Key takeaways
 - Market drivers and constraints
 - Drug class-specific trends
4. **Disease Context**
5. **Epidemiology**
 - Key takeaways
 - Total, diagnosed, and drug-treated prevalent cases of AD by country.
 - MCI due to AD, mild AD, moderate AD, and severe AD.
 - Diagnosed and drug-treated populations
6. **Current Treatment**
 - Key takeaways
 - Treatment for AD
 - Key current therapies
7. **Emerging Therapies**
 - Key takeaways
 - Key emerging therapies
 - Unmet need in AD
8. **Drug Pipeline** (powered by Cortellis)
9. **Appendix**



Report format



In-depth written analyses available on Clarivate's Insights Platform or as a PDF download



Succinct **Executive Summary** deck



Market Forecast Assumptions (flat data file providing comprehensive view of the 10-year, annualized, patient-based market forecast assumptions, including a detailed methodology)




Market Forecast Dashboard (interactive tool to help understand, interpret, explore, and visualize key outputs from the market forecast)

Sample content

Question answered


What are the expected sales of key current and emerging anti-A β MAbs used to treat AD in the G7 markets over the next 10 years?



Sample content

Question answered

What is the current treatment paradigm in AD?



Sample content

Question answered

What are the opinions of clinical thought leaders regarding the therapies in development for neuropsychiatric symptoms in AD?

“Having other approaches that target other mechanisms of action would be very appealing. However, it all comes back to what’s the side-effect profile. With antipsychotics, the concern revolves around the black box warning. It makes it challenging to discuss that with patients, particularly recognizing that these medicines are associated with a higher risk of death within three to six months of being prescribed.”—**Neurologist**, United States

Sample content

Question answered


What clinical unmet needs remain unfulfilled and represent the top opportunities for drug developers?



Sample content

Question answered

How will the launch of an oral DMT offering comparable efficacy to anti-A β MAbs without their associated risks impact the DMT landscape in AD?





About Clarivate

Disease Intelligence and Analytics

Disease intelligence you can trust



Size your market

Understand global and local markets, by gauging the size of the drug treatable population, where they're located, and how populations will change over time.



Identify unmet needs

Identify areas of unmet need and direct your clinical development strategy to the areas with the greatest opportunity.



Fuel successful market access

Optimize your market access strategy with brand-level insight regarding the impact of payer policy on physician prescribing behavior.



Assess and prioritize opportunities

Evaluate market potential for your assets – and those of your competitors – and optimize your strategy with indication-specific market intelligence combined with world-class epidemiology.



Understand the patient journey

Gain visibility into brand usage by line of therapy with RWD and uncover the 'why' behind treatment pathways and brand usage with in-depth coverage of physician perceptions on disease management.



Optimize your brand positioning

Analyze treatment pathways across highly dynamic oncology indications to support brand positioning, strategic planning, and business development.

Find out more

Learn more about how Clarivate can help you maximize your market share:

clarivate.com/products/biopharma/portfolio-strategy-business-development



Think forward™

Contact our experts today:
healthcare.support@clarivate.com
clarivate.com

About Clarivate

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

© 2024 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.